26 March 2020
DBL Pharmaceutical Inc. an American concern of Bangladeshi DBL Group, has achieved notable success in the generic drug market of the United States. In the last quarter, the company was named as the second largest seller of muscle relaxant “Methocarbamol” tablets, according to a recent report by IQVIA – an American health and clinical research company. The market report says, among the 13 generic drug companies selling Methocarbamol in the US, DBL Pharma holds 14.20 percent of the market share.
Methocarbamol is a widely used medicine to treat muscle pain in the US. After the expiration of the proprietary patent of the first marketer of this medicine, mostly Indian generic medicine companies started occupying the market share. By the end of 2018, DBL Group of Bangladesh got approval of the US Food and Drug Administration (FDA) to market this medicine in the United States.
In the first quarter of 2019, DBL Pharma Inc. the concern of DBL group started marketing in America after purchasing the propriety of two generic medicines of the FDA-approved Methocarbamol through contract manufacturing. DBL started with a surprise, as the third Bangladeshi initiative in the US medicine market.
DBL Pharma is hopeful of exporting medicines to other developed countries in future as well to carry forward the thrive for exploring new opportunities.
DBL Pharmaceuticals Ltd. recently held its 1st Annual Business Conference at Hotel Sea Palace, Cox’s Bazar on 5th January 2023. DBL Pharma marked this conference to align its field force with a crafted vision of serving humanity by providing high-quality and differentiated medicines. Deputy Managing Director & Group CEO Mr. M. A. Quader inaugurated the… Continue reading DBL Pharma holds its 1st Annual Business Conference
DBL Pharma celebrates World Heart Day 2022
Cardiovascular disease is a growing burden and one of the leading causes of death in Bangladesh. In most cases, the exact cause of CVD is not known, but a combination of factors can increase the risk of getting heart disease. Considering the risk factors associated with heart disease, DBL Pharma has celebrated “World Heart Day… Continue reading DBL Pharma celebrates World Heart Day 2022